Dr. Hayes is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 E Medical Center Dr
Ann Arbor, MI 48109Phone+1 734-936-4000
Summary
- Medical Oncologist with focus on Breast Cancer at University of Michigan Rogel Cancer Center
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1982 - 1984
- University of Texas Southwestern Medical CenterInternship, Internal Medicine, 1979 - 1980
- Indiana University School of MedicineClass of 1979
Certifications & Licensure
- MA State Medical License 1982 - 2023
- MI State Medical License 2001 - 2023
- DC State Medical License 1996 - 2002
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Join now to see all
Clinical Trials
- Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast Cancer Start of enrollment: 1999 Dec 01
- Aromatase Inhibitor Clinical Trial Start of enrollment: 2005 Jan 01
- A Multi-Center Randomized Clinical Trial Correlating the Effects of 24 Months of Exemestane or Letrozole on Surrogate Markers of Response With Aromatase Polymorphism Start of enrollment: 2005 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- Polypharmacy, over-the-counter medications, and aromatase inhibitor adherence in early-stage breast cancer.Elizabeth Joyce, Xueting Tao, Vered Stearns, Daniel F Hayes, Anna Maria Storniolo
Breast Cancer Research and Treatment. 2024-04-01 - 4 citationsBreast Cancer Circulating Tumor Cells: Current Clinical Applications and Future Prospects.Andi K Cani, Daniel F Hayes
Clinical Chemistry. 2024-01-04 - 2 citationsDual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency.Shane R Stecklein, William Barlow, Lajos Pusztai, Kirsten Timms, Richard Kennedy
JCO Precision Oncology. 2023-09-01
Journal Articles
- An International Multicenter Study to Evaluate Reproducibility of Automated Scoring for Assessment of Ki67 in Breast CancerRichard Levenson, David L Rimm, Daniel F Hayes, Chad Galderisi, Liron Pantanowitz, Nature
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast CancerMatthew P Goetz, Thomas J Saphner, Joseph A Sparano, Lynne I Wagner, Peter M Ravdin, Daniel F Hayes, Adam M Brufsky, Della F Makower, Sunil S Badve, Robert J Gray, Wil..., The New England Journal of Medicine
Other
- Systemic treatment for metastatic breast cancer: General principlesHayes DF
http://www.uptodate.com/contents/systemic-treatment-for-metastatic-breast-cancer-general-principles
UpToDate, Wolters Kluwer Health - 2012-12-06 - Tumor node metastasis (TNM) staging classification for breast cancerHayes DF
http://www.uptodate.com/contents/tumor-node-metastasis-tnm-staging-classification-for-breast-cancer
UpToDate, Wolters Kluwer Health - 2012-04-23 - Measurement of prognostic factors in breast cancerHayes DF
http://www.uptodate.com/contents/measurement-of-prognostic-factors-in-breast-cancer
UpToDate, Wolters Kluwer Health - 2012-10-18 - Join now to see all
Press Mentions
- David Smith Retires with a Legacy of Compassionate Patient CareOctober 16th, 2024
- ASCO Remembers Saul a. Rosenberg, MD, FASCO, ASCO Past President and Pioneer of Hodgkin Lymphoma TreatmentSeptember 7th, 2022
- Xilis Announces Breast Cancer Oncologist Dr. Daniel F. Hayes to Join Clinical Advisory BoardJune 8th, 2022
- Join now to see all
Grant Support
- Effects Of Exemestane Or Letrozole On Surrogate Markers Of ResponseNational Center For Research Resources2007
- Pilot Trial Correlating Metabolic Profile Of Tamoxifen With HOT FlashesNational Center For Research Resources2004–2007
- A Multi-Center Randomized Clinical Trial Correlating The Effects Of 24 Months OfNational Center For Research Resources2006
- Correlative Studies Of Erbb-2/Her2 And P53 In Calgb PRO.National Cancer Institute2003–2005
- Docetaxel (TAXOTERE) &Bcl-2-Antisense OligonucleotideNational Center For Research Resources2000
- Phase 2 Clinical Trials Of Oltipraz In Breast NeoplasiaDivision Of Cancer Prevention And Control1999–2000
- Cancer And Acute Leukemia Group B (CALGB) Inst GrantNational Cancer Institute1998–2000
- Phase II Clinical Trial Of Dehydroepi-AndrosteroneDivision Of Cancer Prevention And Control1999
- Correlative Studies Of Angiogenesis In Breast CancerNational Cancer Institute1996–1997
- Correlative Studies Of Angiogenesis In Breast CancerNational Cancer Institute1994–1996
- Circulating C-NEU Protein In Breast Cancer PatientsNational Cancer Institute1991–1992
- Immunodiagnostic Approaches To Breast CancerNational Cancer Institute1985–1987
Committees
- Member, Expert Panel, American Society of Clinical Oncology (ASCO) 2015 - Present
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: